Each year, several thousand women are diagnosed with DCIS (ductal carcinoma in situ)—abnormal cells confined to the breast's milk ducts. While DCIS can sometimes progress to invasive breast cancer, it often does not. The challenge: accurately predicting which cases will advance.
A pathologist at the Antoni van Leeuwenhoek Hospital in Amsterdam has secured €18 million in funding for pioneering research into this gap. Today, it's impossible to reliably distinguish progressive DCIS from harmless cases, resulting in unnecessary treatments and patient stress. This study promises clearer insights to guide personalized care and avoid overtreatment.
